Can Natalizumab pass the blood-brain barrier?

Natalizumab inhibits the migration of immune cells across the blood-brain barrier, thereby suppressing inflammation in the central nervous system. Typically, this blockage of the blood-brain barrier has significant effects on circulating lymphocytes. To date, only short-term data on peripheral blood parameters are available, mostly from controlled clinical trials rather than from real-world experience. Real laboratory data from 120 patients diagnosed with highly active stages of relapsing-remitting multiple sclerosis (RRMS) during natalizumab treatment were analyzed.

Immature precursor cells, including erythroblasts, were detectable in 36.8% of treated patients during natalizumab treatment but not during pretreatment. Asymptomatic liver enzyme elevations are rare and mostly transient, less than 3 times the upper limit of normal. Renal function parameters remained stable within physiological ranges in most patients.

During natalizumab treatment, only10 patients had CRP levels>20mg/dl, and most of them were related to respiratory infections. In our current analysis, we report a sustained and stable increase in peripheral immune cell subtypes in patients treated with natalizumab. In post-marketing experience, additional serological analyzes confirmed the excellent tolerability and safety profile of natalizumab even 6 years after its initiation.

Natalizumab's original patent drug is not marketed in the country and cannot be included in medical insurance. Currently, the generic drug natalizumab on the market overseas may cost more than 8,000 US dollars per box (the price may fluctuate due to exchange rates), which is very expensive. For more drug information and specific prices, please consult Yaode Medical Consultant.